What this study adds
- In total, 62 severe DDI pairs of LPV/RTV as identified from the FDA
and Liverpool DDI resources should be given serious clinical
considerations predicted to cause life threatening ADRs.
- Of interest, only 10 severe DDI pairs were recognized by both the FDA
and Liverpool DDI resources, further emphasized to undertake
systematic cross-comparisons between DDI resources in order to
identify discrepancies and possibly avoid any interacting drugs that
may cause life-threatening ADRs of LPV/RTV in COVID-19 patients.
- Clinicians should not entirely rely on any individual DDI resource for
checking life threatening ADRs of LPV/RTV in patients with COVID-19
since there were disagreements in enlisting contraindicated drugs.